Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National...
Drug
Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...
Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...
Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
Eisai Co., Ltd. (TYO: 4523) announced the commercial launch of a 14-tablet specification of its...
Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National...
Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval...
Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in...
Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for...
Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved...
AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase...
Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability
Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers...
Gan & Lee Pharmaceuticals’ Once-Weekly Insulin GZR4 Demonstrates Superior HbA1c Reduction in Phase III Trials
Gan & Lee Pharmaceuticals (SHA: 603087) announced that two pivotal Phase III clinical studies, SUPER-1...
Abbisko Therapeutics Secures EMA Orphan Drug Designation for Irpagratinib in Hepatocellular Carcinoma
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the European Medicines Agency (EMA) has granted...
Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor
Abbisko Therapeutics Co., Ltd. (HKG: 2256) has announced FDA clinical trial approval for its investigational...
ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) has announced the first patient dosing in a...
Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial
Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn...
Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...
NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
China’s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)’s Exdensur (depemokimab)...
Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
Kexing Biopharma (SHA: 688136) announced it has received approval from the U.S. Food and Drug...